trending Market Intelligence /marketintelligence/en/news-insights/trending/U-OGUzLg0v4hOHpp9onQlQ2 content esgSubNav
In This List

ContraVir Pharmaceuticals fails to regain Nasdaq compliance

Blog

Japan M&A By the Numbers: Q4 2023

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity

Blog

Insight Weekly: Bank mergers of equals return; energy tops S&P 500; green bond sales to rise


ContraVir Pharmaceuticals fails to regain Nasdaq compliance

The Nasdaq Stock Market LLC notified ContraVir Pharmaceuticals Inc. that it had not regained compliance with the exchange's minimum bid listing requirement of $1 per share.

The exchange further said that ContraVir was not eligible for a second 180-day period since it did not comply with the minimum $5 million stockholders' equity initial listing requirement for The Nasdaq Capital Market.

ContraVir has requested a hearing before the Nasdaq Hearings Panel, staying the delisting process. The panel has the discretion to grant the company an extension through no later than June 2, 2018.